Literature DB >> 12226082

NF-kappa B activation mediates the cross-talk between extracellular matrix and interferon-gamma (IFN-gamma) leading to enhanced monokine induced by IFN-gamma (MIG) expression in macrophages.

Maureen R Horton1, Sada Boodoo, Jonathan D Powell.   

Abstract

In intact tissue, the extracellular matrix (ECM) provides support and helps maintain homeostasis but is considered biologically inert. In the setting of inflammation, not only is the ECM the target of inflammation, but its breakdown products modulate the magnitude and quality of an immune response. Fragments of the ECM component hyaluronan (HA) induce macrophage expression of chemokines, cytokines, and growth factors as well greatly enhance IFN-gamma-induced MIG expression. In this report, we demonstrate that the synergistic induction of MIG by HA and IFN-gamma occurs at the level of transcription via NF-kappaB. Using electrophoretic mobility shift assays and reporter assays, we have identified two NF-kappaB sites proximal to the IFN-gamma-responsive element-1 (gammaRE-1) that mediate this effect. Interestingly, our experiments also revealed a critical role for NF-kappaB in mediating IFN-gamma-induced MIG expression independent of HA. These data emphasize the ability of "degraded self" to activate/modify immune responses through the NF-kappaB pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226082     DOI: 10.1074/jbc.M206007200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Authors:  Vinata B Lokeshwar; Luis E Lopez; Daniel Munoz; Andrew Chi; Samir P Shirodkar; Soum D Lokeshwar; Diogo O Escudero; Neetika Dhir; Norman Altman
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 2.  Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal.

Authors:  Jonathan D Powell; Maureen R Horton
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

4.  Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates.

Authors:  Martin D Rees; Clare L Hawkins; Michael J Davies
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

5.  The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion.

Authors:  Kara A Scheibner; Sada Boodoo; Samuel Collins; Katharine E Black; Yee Chan-Li; Paul Zarek; Jonathan D Powell; Maureen R Horton
Journal:  Am J Respir Cell Mol Biol       Date:  2008-08-14       Impact factor: 6.914

Review 6.  The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.

Authors:  Eleni Papakonstantinou; George Karakiulakis
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 7.  Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease.

Authors:  Alba B Souza-Fernandes; Paolo Pelosi; Patricia R M Rocco
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

8.  Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Authors:  Fernando Ramos; Cristina Robledo; Francisco Miguel Izquierdo-García; Dimas Suárez-Vilela; Rocío Benito; Marta Fuertes; Andrés Insunza; Eva Barragán; Mónica Del Rey; José María García-Ruiz de Morales; Mar Tormo; Eduardo Salido; Lurdes Zamora; Carmen Pedro; Javier Sánchez-Del-Real; María Díez-Campelo; Consuelo Del Cañizo; Guillermo F Sanz; Jesús María Hernández-Rivas
Journal:  Oncotarget       Date:  2016-05-24

Review 9.  Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation.

Authors:  Helena Crijns; Vincent Vanheule; Paul Proost
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.